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Background: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate
cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are
not well captured by the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST)
criteria. Several surrogate markers for evaluation of cancer vaccine, including prostate-specific antigen doubling time
(PSADT), are currently sought. The purpose of this study was to assess prospectively the PSA kinetics and immune
responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC.
Methods: One hundred patients with progressive CRPC were treated with PPV using 2–4 positive peptides from
31 candidate peptides determined by both human leukocyte antigen (HLA) class IA types and the levels of
immunoglobulin G (IgG) against each peptide. The association between immune responses and PSADT as well as
overall survival (OS) was studied.
Results: PPV was safe and well tolerated in all patients with a median survival time of 18.8 months. Peptide-specific
IgG and T-cell responses strongly correlated with PSADT (p < 0.0001 and p = 0.0007, respectively), which in turn showed
correlation with OS (p = 0.018). Positive IgG responses and prolongation of PSADT during PPV were also significantly
associated with OS (p = 0.001 and p = 0.004) by multivariate analysis.
Conclusions: PSADT could be an appropriate surrogate marker for evaluation of the clinical benefit of cancer vaccine.
Further randomized trials are needed to confirm these results.
Trial registration: UMIN000001850
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Changes in serum prostate-specific antigen (PSA) can
reflect the burden of disease and clinical benefit in
patients with castration-resistant prostate cancer (CRPC)
with cytotoxic chemotherapy or hormonal agents known
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reproduction in any medium, provided the orby providing and updating prognostic information on an
individual patient over time [1-4]. As observed in many
clinical trials, however, immunotherapy can induce novel
patterns of antitumor responses distinct from those of
chemotherapy [5]. For example, an autologous dendritic-cell-
based vaccine (sipuleucel-T) is known to improve survival
without having an impact on early PSA decline [6],
whereas docetaxel's improvement in overall survival (OS)
correlates for the most part with a PSA decline within the
first 3 months of therapy [7,8]. Thus, interpreting PSA
decline in the context of novel immunotherapy must bel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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action, and may also depend on the time of sampling [9].
Personalized peptide vaccine (PPV) uses multiple
peptides based on the pre-existing immunity. Under
PPV treatment, each patient with human leukocyte
antigen (HLA)-class IA types positive was tested for
their immunological reactivity to 31 different peptides
capable of inducing T-cell responses. The 31 peptides were
derived from a number of tumor associated antigens:
PSA, prostatic acid phosphatase (PAP), prostate-specific
membrane antigen (PSMA), multidrug resistance protein
and a variety of other epithelial tumor antigens. We
previously demonstrated that PPV was safe and improved
OS with immune responses in phase I, I/II, and II clinicalTable 1 Peptide candidates for personalized peptide vaccinat
Symbol for peptide Origin protein Position of p
CypB-129 Cyclophilin B 129-138
Lck-246 p56 lck 246-254



















Lck-486 p56 lck 486-494






Lck-90 p56 lck 90-99
Lck-449 p56 lck 449-458
PAP-248 PAP 248-257
aA3sup, HLA-A3 supertype (A3, A11, A31, and A33).trials in patients with CRPC [10-16]. However, it was
not addressed whether PSADT could be an appropriate
surrogate marker for evaluation of the clinical benefit
of cancer vaccine. To address this, we evaluated data
from a phase II clinical trial for CRPC using PPV.
Methods
Patient Eligibility
Eligibility required a histological diagnosis of prostate
adenocarcinoma and progressive disease (PD) defined as
at least two consecutive increases in PSA, new metastatic
lesion on radionuclide bone scan, or progressive tumor
lesions on cross-sectional imaging, despite adequate
androgen ablative therapy. Patients showed positive IgGion
































Table 2 Patient characteristics






































Bone and nodal/organ 40





Abbreviations: PPV, personalized peptide vaccination; ECOG, Eastern
Cooperative Oncology Group; HLA, human leucocyte antigen; PSA,
prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein;
SAA, serum amyloid A; IL6, interleukin 6.
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peptides (Table 1). Any number of previous hormonal
therapies was allowed. Patients were required to wait
at least four weeks for entry into the study after the
completion of prior radiation therapy, chemotherapy,
or a change in hormonal therapy. Other inclusion criteria
included age ≥ 20 years; Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1; life expectancy
of at least 12 weeks; positive status for HLA-A2, -A24, -A3
supertype (−A3, -A11, -A31, and -A33), or -A26; adequate
hematologic, hepatic, and renal function; and negative
status for hepatitis virus B and C. Exclusion criteria
included an acute infection; a history of severe allergic
reactions; pulmonary, cardiac, or other systemic diseases;
and other inappropriate conditions for enrollment as
judged by clinicians.
Study design and treatment
This was a single institution, single arm, open-label, phase
II study. The endpoints of this study were primarily safety
and feasibility of PPV in patients with CRPC. Secondary
endpoints were to assess the PSA kinetics and immune
responses. In addition, we identified potential factors for
predicting OS and selecting suitable patients for this treat-
ment. This study protocol was approved by Kurume Uni-
versity Ethical Committee. Written informed consent was
obtained from all patients before any study procedures.
In this study, 31 peptides, whose safety and im-
munological effects had been confirmed in previously
conducted clinical studies [10-18], were employed for
vaccination [12 peptides for HLA-A2, 14 peptides for
HLA-A24, 9 peptides for the HLA-A3 supertype (A3,
A11, A31, or A33), and 4 peptides for HLA-A26] (Table 1).
All peptides were prepared under conditions of Good
Manufacturing Practice using a Multiple Peptide System
(San Diego, CA). The selection of 2 to 4 peptides for
vaccination to each patient was based on HLA typing
and high titer level of peptide-specific IgG to candidate
peptides. Each of the selected peptides was mixed with
incomplete Freund’s adjuvant (Montanide ISA-51VG;
Seppic, Paris, France) and emulsified in the 5 ml plastic
syringe, and a maximum of four peptides of 1.5 ml
emulsion (3 mg/peptide) were injected subcutaneously
into the lateral thigh area once a week for 6 weeks. The
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IgG levels at every cycle of 6 vaccinations and adminis-
tered at 2-, 3-, or 4-week intervals until withdrawal of
consent or unacceptable toxicity.
Assessment of clinical activity
Patients were monitored at each visit by history and
physical examinations. Serum PSA test and routine labora-
tory studies were performed every 6 vaccinations for
any adverse effects. Toxicity was graded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0 (NCI-CTCAE Ver3).
All patients underwent relevant radiologic studies
and bone scans every 6 months or at the progression of
symptoms. PD was defined as radiographic progression
evaluated by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [19] or clinical progression.
To assess the PSA response for each patient, percent
PSA change from baseline was calculated for each phase
of the study (pre- and during vaccination). In addition,
PSA doubling time (PSADT) was calculated using all
serum PSA values for a specified period, and using a
minimum of three PSA values by the formula log2/b,
where b denotes the least square estimate of the linear
regression model of the log-transformed PSA values on
time. For analytical purposes, negative PSADT estimates
and high positive PSADT estimates (>36 months) were
censored at 36 months.
To investigate biomarkers for OS that may allow
patient selection and prediction of a response to PPV,Table 3 Adverse events during peptide vaccination
Grade 1
















Blood triglycerides increased 10
Creatinine increased 6serum amyloid A (SAA), C-reactive protein (CRP), and
interleukin (IL)-6 in plasma at baseline were addition-
ally examined by enzyme-linked immunosorbent assay
(ELISA), respectively.
Measurement of humoral and T-cell responses specific to
the vaccinated peptides
To study the humoral responses specific to the vaccinated
peptides, peptide-specific IgG levels were measured by
a Luminex system (Luminex, Austin, TX), as reported
previously [20]. If the total titers of selected peptide-
specific IgG in any cycles of post-vaccination plasma
were more than 2-fold higher than those in the pre-
vaccination plasma, the changes were considered to be
a positive response.
Although T-cell subsets using flowcytometry was not
analyzed in this study, T-cell responses specific to the
vaccinated peptides were evaluated by IFN-γ ELISPOT
assay using peripheral blood mononuclear cells (PBMCs),
as reported previously [18]. Peptide-specific T-cell responses
were evaluated by the differences between the numbers of
spots per 105 x PBMCs in response to the vaccine peptides
and those to the control peptide at pre- and 6th vaccination;
at least 2-fold more spots at the 6th vaccination than at
pre-vaccination was considered positive.
Statistical analysis
All patients who received more than 6 vaccinations were
considered evaluable for tumor response, and all patients
















Figure 1 PSA kinetics and overall survival. (A) Waterfall plot showing the maximal PSA changes (%) from baseline during personalized peptide
vaccination (PPV) at any time point. (B) Overall survival by >50% PSA decline. (C) The ratio of PSADT changes for each patient pre- and during
PPV is plotted. The ratio of PSADT changes was calculated by dividing PSADT during treatment by pre-treatment PSADT. A ratio greater than
2 indicates prolongation of PSADT. (D) Overall survival by prolongation of PSDT. (E) Longitudinal average PSA changes (%) before and during
PPV. Green histograms: Responder group (alive for more than 20 months). Red histograms: Non-responder group (death within 12 months).
Gray histograms: Other group.
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cially available computer software. The Student’s t-test
and the chi-square test were used to compare quantitative
and categorical variables, respectively. Survival was calcu-
lated from the date of first treatment until the date of any
cause of death. Patients lost to follow-up were censored at
the last known date of survival. The Kaplan-Meier method
was used to estimate actuarial survival curves, and groups
were compared using a log-rank test. Cox proportional
hazards regression model was used for univariate and
multivariate analyses to identify factors that had a sig-
nificant impact on survival. All baseline parameters in
the survival and proportional hazards regression analysis
were analyzed as dichotomous variables using median orFigure 2 Positive immune responses of IgG and CTL based on baselincut-off values. A two-sided significance level of 5% was
considered statistically significant.
Results
Characteristics of the patients
Between April 2009 and August 2011, 100 patients with
CRPC were enrolled in this trial at Kurume University
Hospital. All 100 patients received at least one vaccination
with a median of 16 vaccinations (range, 1 to 40) and were
included in the safety assessment and survival analysis.
Three patients did not complete 6 vaccinations (1 cycle)
and were excluded from the assessment of PSA response
and immune responses. The reason for these failures to
complete 6 vaccinations was withdrawal of consent. Thee characteristics.
Figure 3 Comparing immune responses with PSA kinetics.
(A) Change in PSA from baseline (%) based on immune responses.
(B) Ratio of PSADT based on immune responses.
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years), and the ECOG performance status was 0 in 91of
the patients and 1 in the remaining 9. The median PSA
and pre-vaccination PSADT at the entry to the study
was 29.8 ng/ml (range, 0.2 to 2481 ng/ml) and 2 months
(range, 0.3 to 36+ months), respectively. Fifty-seven
patients had a Gleason score of ≥ 8 and 86 patients had
metastasis. All patients had experienced progression after
androgen deprivation therapy as an initial or secondary
therapy. Forty patients had received docetaxel based
chemotherapy with a median cycle of 6.5 as a third line
treatment. Baseline patient characteristics are shown
in Table 2.
Adverse events
The overall toxicities are shown in Table 3. The most
frequent adverse events were local redness and swelling
at injection sites, bone pain, hypoalbuminemia, lympho-
cytopenia, appetite loss, fatigue, increased ALP, and
anemia, which were grade 1 or 2 in most cases. There
were no grade 4 toxicities and no treatment-related
deaths. A total of 51 grade 3 toxicities including anemia,
bone pain, increased ALP, lymphocytopenia, decreased
white blood cells, increased creatinine, injection site
reaction, and increased AST and ALT were observed
during the study. All of these severe adverse events were
concluded to be not directly associated with the vaccina-
tions, but with cancer progression or other causes by the
independent safety evaluation committee in this trial.
Clinical outcome
Forty-eight (49%) patients exhibited some decrease in PSA
from baseline, ranging from 1.9% to 99.6% (Figure 1A).
Confirmed ≥50% PSA decline at any point during PPV
was observed in 21 patients (22%), with a median time
of 4 months to ≥50% PSA decline and a median dur-
ation of ≥50% PSA decline of 3 months. Delayed PSA
response was observed. Patients with ≥50% PSA decline
during PPV showed longer survival than remaining
patients ( p = 0.035) (Figure 1B). The median estimated
PSADT pre- and during PPV were 2 and 3.89 months,
respectively. Fifty-four (56%) patients displayed at least
2-fold increase over the pre-treatment PSADT (range,
2.1- to 75-fold), and these patients with a prolongation
of PSADT showed longer survival than patients without
a prolongation of PSADT (p = 0.013) (Figure 1C and
D). To compare the difference in PSA responses with
clinical outcomes, patients were divided into three
groups: responder group with survival longer than 20
months after PPV, non-responder group with death
within 12 months after PPV, and another group with
the remaining patients. Average% PSA changes in the
responder group were significantly lower than those in
the non-responder group at 2 to 5 months (p < 0.005)and those in the other group at 5 to 10 months (p <
0.005) during the PPV. In addition, average% PSA
changes in the responder group showed a trend of
PSA plateau. Average% PSA changes from baseline
among three groups before and during PPV are shown
in Figure 1E.
There was no complete response or partial response in
terms of measurable disease. The median time to disease
progression, as defined by clinical and/or radiologic criteria,
was 10.9 months (95% CI, 6 to 19 months). At the time of
analysis with a median follow-up of 18 months (95% CI,
14.1 to 24 months), 64 deaths had occurred. Median
survival time was 18.8 months (95% CI, 14.9 to 28.6 months)
in all patients. Median survival time in chemotherapy naive
patients and in patients after docetaxel chemotherapy were
21.6 months and 11.6 months, respectively.
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The number of selected peptides were 4 peptides in 62
patients, 3 peptides in 17 patients and 2 peptides in 21
patients at the first screening. Same peptide at the first
screening were only selected in 29 of 97 (30%) patients
at second screening and in 10 of 66 (15%) patients at the
third screening, remaining patients received at least 1
different peptide during the study. The most frequently
selected peptides were Lck486 (40 patients), CypB129
(31 patients), PAP213 (24 patients), SART2-93 (21 patients),
PSA248 (20 patients), Lck488 (17 patients) and WHSC2-
123 (16 patients) at the first screening. All 31 peptides
were selected at any screening in the study.
Total IgG responses specific to the vaccinated peptide
were augmented in 42 of 97 (43%) patients, 62 of 66
(94%) patients, 36 of 36 (100%) patients, 16 of 16 (100%)
patients, and 7 of 7 (100%) patients at the 6th, 12th, 18th,
24th, and 30th vaccinations, respectively. Finally, positive
IgG responses during PPV were observed in 76/97 (79%)
patients. PBMCs from 97 patients were available for IFN-γ
Elispot assay at the pre- and 6th vaccination. Peptide-
specific T-cell responses were detectable in 42 patients
(43%) at the 6th vaccination. There was no obvious correl-
ation between IgG and CTL responses. Positive immune
responses of both IgG and CTL based on baseline charac-
teristics including age, PS, HLA typing, PSA, Gleason score,
presence of metastasis and prior chemotherapy are shown
in Figure 2. There was no difference in positive immune
responses among baseline characteristics. In comparing
immune responses with PSA kinetics, although average
PSA changes did not correlate with immune responses,Table 4 Cox proportional hazards regression analysis of asso
the 100 CRPC patients
Factors Cut-offsa
p value H
IgG response Positive vs. negative <0.0001
ECOG performance status 0 vs. 1 <0.0001
CRP Low (<3000 ng/mL) vs. high 0.012
PSADT Increase (2 times) vs. no 0.018
PSA Low (<30 ng/mL) vs. high 0.004
Prior chemotherapy Untreated vs. treated 0.037
T-cell response Positive vs. negative 0.039
>50% PSA decline Positive vs. negative 0.046
Number of lymphocytes High (>1300/μL) vs. low 0.054
IL6 Low (<2.4 pg/mL) vs. high 0.057
Pts. age Low (<69 years) vs. high 0.186
Gleason score Low (<8) vs. high 0.623
SAA Low (<8 μg/mL) vs. high 0.709
Of the 100 men, 64 died.
aLymphocyte, PSA, and patient age are based on median values.
Abbreviations: PPV, personalized peptide vaccination; CRPC, castration-resistant pros
Group; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive praverage ratio of PSADT was significantly higher in patients
with positive IgG (8 vs. 4, p < 0.0001) and CTL (8.8 vs. 6.1,
p = 0.0007) responses (Figure 3).
Survival analysis
Cox proportional hazards regression analysis was per-
formed to determine factors that would predict disease
death (Table 4). Univariate Cox analysis showed that good
performance status (p < 0.0001), positive IgG response
(p < 0.0001), low CRP (p = 0.012), prolongation of PSADT
(p = 0.018), low PSA (p = 0.004), prior chemotherapy
status (p = 0.037), positive T-cell response (p = 0.039), and
presentation of ≥50% PSA decline (p = 0.046) were signifi-
cantly associated with survival.
The factors showing p less than 0.05 in the univariate
analysis were included in multivariate analysis of the model.
Finally, positive IgG response (p = 0.001) and prolongation
of PSADT (p = 0.004) during PPV, as well as baseline good
performance status (p = 0.004), low CRP levels (p = 0.006),
and low PSA levels (p = 0.008), were significantly favorable
factors for OS (Table 4).
Discussion
As observed in several clinical trials, immunotherapy can
induce novel patterns of antitumor responses distinct
from those of chemotherapy, which are consequently
not captured by the WHO or RECIST criteria [5]. On
the other hand, there is debate regarding the utility of
PSA changes, especially with immunotherapy, and the
PSA Working Group 2 has advocated using radiographic
progression-free survival as a preferred endpoint for phaseciation between potential factors and death after PPV in
Univariate Multivariate
azard ratio 95% CI p value Hazard ratio 95% CI
0.19 0.101-0.355 0.001 0.272 0.125-0.592
0.073 0.031-0.174 0.004 0.179 0.056-0.569
0.461 0.252-0.842 0.006 0.389 0.199-0.759
0.477 0.258-0.881 0.004 0.357 0.176-0.725
0.407 0.221-0.749 0.008 0.361 0.171-0.762
0.536 0.298-0.962 0.329 0.695 0.335-1.445
0.51 0.269-0.967 0.273 0.679 0.340-1.357
0.387 0.152-0.984 0.553 0.733 0.263-2.042
0.562 0.313-1.009 - - -
0.491 0.236-1.021 - - -
0.666 0.364-1.218 - - -
1.162 0.637-2.128 - - -
0.875 0.433-1.767 - - -
tate cancer; CI, confidence intervals; ECOG, Eastern Cooperative Oncology
otein; SAA, serum amyloid A; IL6, interleukin 6.
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may be a marker of drug effect, understanding that shorter
PSADT corresponds to worse prognosis and, thus, a favor-
able change in PSADT suggests drug activity [22,23].
However, clinical trials of recently developed drugs,
such as sipuleucel-T [6], cabazitaxel [24], and abiraterone
acetate [25], for the treatment of progressive CRPC
patients did not analyze the usefulness of PSADT as a
surrogate marker of response in CRPC patients. In the
current study, we attempted careful and stringent col-
lection of multiple PSA values in order to calculate
PSADT changes before and during PPV accurately.
While delayed PSA responses were observed, we did see a
statistically significant increase in PSADT. Importantly,
patients with prolongation of PSADT showed statistically
longer survival (p = 0.018). These results suggest that the
development of late immune responses is associated with
changes in PSADT.
The evaluation of T-cell immune responses to target
self antigens after vaccine clinical trials presents several
challenges. Antigen-specific T-cells can be evaluated by
their peptide target specificity, proliferative capacity,
cytokine secretion, cytolytic activity, and membrane
markers of activation. At present, the best measure of
antigen-specific T-cells is unknown, as is the optimal time
to evaluate immune responses. In our current analysis,
we evaluated both humoral responses determined by
peptide-specific IgG levels using a Luminex system and
antigen-specific CD8+ T-cell responses by using IFN-γ
ELISPOT assays, to provide a more direct quantitative
assessment after immunization. Delayed 50% PSA decline
and prolongation of PSADT were observed in patients
with positive IgG and T-cell respkonses, and these im-
mune responses were associated with OS. These results
suggest that further immunological analysis at multiple
time points might be needed to determine whether T-cell
response or the development of late immune responses is
associated with clinical responses.
Cancer vaccinations do not always extract good immune
and/or clinical responses in vaccinated patients. This study
showed that IgG responses and prolongation of PSADT
during PPV, along with baseline performance status, CRP,
and PSA levels, were well correlated with OS in patients
with CRPC treated by PPV. These results suggest that
risk stratification based on these factors could be helpful
for estimating the OS in patients with CRPC treated by
immunotherapy.
Despite these encouraging observations, the current
study must be interpreted as hypothesis-generating due
to several limitations. This single-arm phase II study
without a concurrent control arm did not allow estimation
of the potential clinical or immune effects of this treat-
ment. Another potential limitation of this study regarding
OS is the lack of treatment data after the treatment phaseof the trial. Imbalances due to chance may have occurred
in treatments after progression. However, only docetaxel
has been shown to affect survival in this population of
patients, and only by a few months. The median survival
of 18.8 months (95% CI, 14.1 to 24 months) observed in
this study surpassed the survival that was observed from
docetaxel-based clinical trials in a similar population by
TAX-327 (median survival, 19.2 months) and South West
Oncology Group 9906 (median survival, 17.5 months)
[7,8]. Thus, we think it unlikely that a potential imbalance
in post-study treatments could explain the survival results.
Conclusions
This study showed that PPV in patients with CRPC was
active and well tolerated, improving survival with immune
responses, delayed PSA responses, and prolongation of
PSADT. Further randomized trials are needed to confirm
these preliminary results.
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